Targeting the JAK/STAT pathway in cytotoxic T lymphocytes (CTL) by Next Generation Sequencing (NGS)

Next Generation Sequencing (NGS), together with our evolving knowledge of genes and disease, is likely to change the current practice of medicine and public health by facilitating more accurate, sophisticated, and cost-effective genetic testing. Here, we propose a new molecular approach by using MiSeq Sequencing System (Illumina) to investigate the presence of mutations/variants in genes of JAK/STAT pathway involved in different cytotoxic T lymphocytes (CTL)-mediated immune disorders and to develop and validate new and less expensive molecular protocol based on Next Generation Sequencing.